Herein, we demonstrate that MYC protein expression by IHC represents a rapid and inexpensive marker to identify MYC overexpression in DLBCL, including patients harboring MYC translocations, and that ...

Nexus Pharmaceuticals shared that on May 9, 2025, it won a patent litigation involving injectable cyclophosphamide, a drug that has been approved for certain kinds of cancer. Nexus had been ...

In January 2021, the FDA granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro) in combination with bortezomib (Velcade), cyclophosphamide and dexamethasone for patients with ...

Patients in the IMA203 arm will undergo lymphodepletion with cyclophosphamide (500 mg/m 2 x 4 days) and fludarabine (30 mg/m 2 x 4 days), subsequent infusion of 1-10 x10 9 IMA203 PRAME-directed TCR T ...

Sevabertinib (BAY 2927088) could lead to high and comparable objective response rates (ORRs) for the treatment of patients with HER2-mutant non–small cell lung cancer (NSCLC) who were pretreated but ...

Existing guidelines for systemic lupus erythematosus (SLE) predominantly focus on common and major organ involvements. An international taskforce involving experts from three SLE expert groups (ie, ...

Clinicopathological features and prognostic implications of HER2-low in early-stage male breast cancer: A retrospective analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.